Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
A new method developed at LMU overcomes fundamental resolution limits and may provide insights into high-temperature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results